Last checked at 11 Jun 2020 14:00
11 June 2020
Diaceutics PLC
("Diaceutics", the "Company" or the "Group")
Exercise of Warrant
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it has received notification for the exercise of a warrant over 347,915 ordinary shares in the Company at an exercise price of 76 pence per share providing the Company with proceeds of £264,415 ("Warrant Exercise").
Application has been made to the London Stock Exchange to admit the 347,915 new ordinary shares resulting from the Warrant Exercise to trading on AIM ("Admission"), which is expected to occur on 16 June 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above and including the 10,437,000 Firm Placing shares to be issued in connection with the Firm Placing announced yesterday by the Company, on 16 June 2020 the Company's issued share capital admitted to trading on AIM will comprise 80,367,992 ordinary shares of 0.2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
Enquiries
Diaceutics PLC |
|
Stuart Hunt, Head of Investor Relations | Tel: +44 (0)7815 778 536 |
|
|
Cenkos Securities PLC (Nomad & Broker) | Tel: +44(0)20 7397 8900 |
Callum Davidson / Giles Balleny |
|
Michael Johnson (Sales)
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com |
Anna Dunphy | Tel: +44 (0)7876 741 001 |
Paul McManus | Tel: +44 (0)7980 541 893 |
About Diaceutics
Diaceutics PLC is a diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com